|
1.
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
|
|
2.
|
Yang HI, Lu SN, Liaw YF, You SL, Sun CA,
Wang LY, Hsiao CK, Chen PJ, Chen DS and Chen CJ; Taiwan
Community-Based Cancer Screening Project Group: Hepatitis B e
antigen and the risk of hepatocellular carcinoma. N Engl J Med.
347:168–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
4.
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, et al
Barcelona Liver Cancer Group: Arterial embolisation or
chemoembolisation versus symptomatic treatment in patients with
unresectable hepatocellular carcinoma: a randomised controlled
trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar
|
|
5.
|
Palmer DH, Hussain SA and Johnson PJ:
Systemic therapies for hepatocellular carcinoma. Expert Opin Invest
Drugs. 13:1555–1568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
9.
|
Furuse J: Sorafenib for the treatment of
unresectable hepato-cellular carcinoma. Biologics. 2:779–788.
2008.PubMed/NCBI
|
|
10.
|
Abou-Alfa GK, Letourneau R, Harker G,
Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager
RL, Eckhardt SG and O'Reilly EM: Randomized phase III study of
exatecan and gemcitabine compared with gemcitabine alone in
untreated advanced pancreatic cancer. J Clin Oncol. 24:4441–4447.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yau T, Chan P, Ng KK, Chok SH, Cheung TT,
Fan ST and Poon RT: Phase 2 open-label study of single-agent
sorafenib in treating advanced hepatocellular carcinoma in a
hepatitis B-endemic Asian population: presence of lung metastasis
predicts poor response. Cancer. 115:428–436. 2009. View Article : Google Scholar
|
|
12.
|
Vincenzi B, Santini D, Russo A, Addeo R,
Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M,
et al: Early skin toxicity as a predictive factor for tumor control
in hepatocellular carcinoma patients treated with sorafenib.
Oncologist. 15:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L and Colombo
M: Clinical management of hepatocellular carcinoma. Conclusions of
the Barcelona-2000 EASL conference. European Association for the
Study of the Liver. J Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: the BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar
|
|
16.
|
Wang C, Lu Y, Chen Y, Feng Y, An L, Wang
X, Su S, Bai W, Zhou L, Yang Y and Xu D: Prognostic factors and
recurrence of hepatitis B-related hepatocellular carcinoma after
argon-helium cryoablation: a prospective study. Clin Exp
Metastasis. 26:839–848. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Furuse J, Ishii H, Nakachi K, Suzuki E,
Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese
patients with hepatocellular carcinoma. Cancer Sci. 99:159–165.
2008.PubMed/NCBI
|
|
19.
|
Rabe C, Pilz T, Klostermann C, Berna M,
Schild HH, Sauerbruch T and Caselmann WH: Clinical characteristics
and outcome of a cohort of 101 patients with hepatocellular
carcinoma. World J Gastroenterol. 7:208–215. 2001.PubMed/NCBI
|
|
20.
|
Han KH, Seong J, Kim JK, Ahn SH, Lee DY
and Chon CY: Pilot clinical trial of localized concurrent
chemoradiation therapy for locally advanced hepatocellular
carcinoma with portal vein thrombosis. Cancer. 113:995–1003. 2008.
View Article : Google Scholar
|
|
21.
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar
|
|
22.
|
Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY and
Mack P: Experience with liver resection after hepatic arterial
chemoembolization for hepatocellular carcinoma. Cancer. 71:62–65.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kim YB, Park YN and Park C: Increased
proliferation activities of vascular endothelial cells and tumour
cells in residual hepato-cellular carcinoma following transcatheter
arterial embolization. Histopathology. 38:160–166. 2001. View Article : Google Scholar
|
|
24.
|
Poon RT, Ng IO, Lau C, Yu WC, Fan ST and
Wong J: Correlation of serum basic fibroblast growth factor levels
with clinicopathologic features and postoperative recurrence in
hepatocellular carcinoma. Am J Surg. 182:298–304. 2001. View Article : Google Scholar
|
|
25.
|
Ng IO, Poon RT, Lee JM, Fan ST, Ng M and
Tso WK: Microvessel density, vascular endothelial growth factor and
its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J
Clin Pathol. 116:838–845. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hinshaw JL and Lee FT Jr: Cryoablation for
liver cancer. Tech Vasc Interv Radiol. 10:47–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Yang Y, Wang C, Lu Y, Bai W, An L, Qu J,
Gao X, Chen Y, Zhou L, Wu Y, et al: Outcomes of ultrasound-guided
percutaneous argon-helium cryoablation of hepatocellular carcinoma.
J Hepatobiliary Pancreat Sci. Dec 21–2011.(E-pub ahead of
print).
|
|
28.
|
Hakimé A, Hines-Peralta A, Peddi H, Atkins
MB, Sukhatme VP, Signoretti S, Regan M and Goldberg SN: Combination
of radiofrequency ablation with antiangiogenic therapy for tumor
ablation efficacy: study in mice. Radiology. 244:464–470.
2007.PubMed/NCBI
|
|
29.
|
Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL,
Zhang ZL and Yi CH: Chemoembolization combined with radiofrequency
ablation for patients with hepatocellular carcinoma larger than 3
cm: a randomized controlled trial. JAMA. 299:1669–1677. 2008.
View Article : Google Scholar
|
|
30.
|
Wörns MA, Weinmann A, Pfingst K,
Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A,
Schuchmann M, Kanzler S, Düber C, et al: Safety and efficacy of
sorafenib in patients with advanced hepatocellular carcinoma in
consideration of concomitant stage of liver cirrhosis. J Clin
Gastroenterol. 43:489–495. 2009.PubMed/NCBI
|
|
31.
|
Grothey A, Hedrick EE, Mass RD, Sarkar S,
Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM and Sargent DJ:
Response-independent survival benefit in metastatic colorectal
cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol.
26:183–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Llovet JM, Bustamante J, Castells A,
Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J and Bruix J: Natural
history of untreated nonsurgical hepatocellular carcinoma:
rationale for the design and evaluation of therapeutic trials.
Hepatology. 29:62–67. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Si MS, Amersi F, Golish SR, Ortiz JA, Zaky
J, Finklestein D, Busuttil RW and Imagawa DK: Prevalence of
metastases in hepatocellular carcinoma: risk factors and impact on
survival. Am Surg. 69:879–885. 2003.PubMed/NCBI
|
|
34.
|
Li M, Li H, Li C, Guo L, Liu H, Zhou S,
Liu X, Chen Z, Shi S, Wei J, et al: Cytoplasmic alpha-fetoprotein
functions as a co-repressor in RA-RAR signaling to promote the
growth of human hepatoma Bel 7402 cells. Cancer Lett. 285:190–199.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Li M, Li H, Li C, Zhou S, Guo L, Liu H,
Jiang W, Liu X, Li P, McNutt MA and Li G: Alpha fetoprotein is a
novel protein-binding partner for caspase-3 and blocks the
apoptotic signaling pathway in human hepatoma cells. Int J Cancer.
124:2845–2854. 2009. View Article : Google Scholar : PubMed/NCBI
|
